Sodium-orthovanadate-Sodium-vanadate-DataSheet-MedChemExpress_第1頁(yè)
Sodium-orthovanadate-Sodium-vanadate-DataSheet-MedChemExpress_第2頁(yè)
Sodium-orthovanadate-Sodium-vanadate-DataSheet-MedChemExpress_第3頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESodium orthovanadateCat. No.: HY-D0852CAS No.: 13721-39-6Synonyms: Sodium vanadate分式: NaOV分量: 183.91作靶點(diǎn): Phosphatase作通路: Metabolic Enzyme/Protease儲(chǔ)存式: 4C, protect from light* In solvent : -80C, 6 months; -20C, 1 month (protect f

2、romlight)溶解性數(shù)據(jù)體外實(shí)驗(yàn) H2O : 200 mg/mL (1087.49 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 5.4374 mL 27.1872 mL 54.3744 mL5 mM 1.0875 mL 5.4374 mL 10.8749 mL10 mM 0.5437 mL 2.7187 mL 5.4374 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVI

3、TY物活性 Sodium orthovanadate蛋酪氨酸磷酸酶,堿性磷酸酶和些ATP酶的抑制劑,最有可能充當(dāng)磷酸鹽類似物。IC50 & Target PPTPase 1.體外研究In the presence of oxidizing agents vanadium ions exist as the hydrated monomer of Sodium orthovanadate1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE(vanadate: HVO42- or H2VO4-) at micromolar concentations

4、near neutral pH. Sodium orthovanadate(vanadate) also begins to polymerize at concentrations greater than 0.1 mM at neutral pH. The yellow-orangesolutions of decavanadate can be converted to the colorless solutions of monomeric Sodium orthovanadate(vanadate) by dilution after a period of many hours.

5、The process is hastened by boiling at pH 10, whichencourages the kinetically sluggish depolymerization process 1. Sodium orthovanadate could alter thephosphorylation status of ASK1 at serine 83 and threonine 845 induced by ischemia. Sodium orthovanadatecould increase the tyrosine posphorylation of P

6、TEN and further inhibit the activation of ASK1 via activatingAkt during cerebral ischemia 2.REFERENCES1. Gordon JA, et al. Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods Enzymol. 1991;201:477-82.2. Wu DN, et al. Down-regulation of PTEN by sodium orthovanadate inhibits ASK1 activation via PI3-K/Akt during cerebral ischemia in rathippocampus. Neurosci Lett. 2006 Aug 14;404(1-2):98-102.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.T

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論